AID-mediated somatic hypermutation for generation of viral envelope protein diversity in patient-specific therapeutic HIV vaccines based on induction of neutralizing antibodies.
The somatic hypermutation (SHM) hypothesis for R5-X4 HIV-1 switching has recently received experimental support. AID-mediated SHM in B cell lines can be used to generate patient's HIV-1 envelope protein diversity in vitro for subsequent vaccination of HIV-1-infected patient at the beginning of asymptomatic period with a resulting mixture of mutant envelope proteins. Suggested approach, which represents a vaccination against R5-X4 HIV-1 switching, might open possibilities for creation of patient-specific therapeutic HIV vaccines based on induction of neutralizing antibodies.
Suslov
Konstantin V
KV
Russian State Medical University, 1 Ostrovityanov St, Moscow 117 997, Russia. suslov_kv@mail.ru
D016915:AIDS Vaccines; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology*; D057134:Antibodies, Neutralizing; D000940:Antigenic Variation; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism; D002460:Cell Line; D000939:Epitopes / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015497:HIV-1 / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D050505:Mutant Proteins / Q000276:immunology; D027041:Somatic Hypermutation, Immunoglobulin
D016915:AIDS Vaccines; D057134:Antibodies, Neutralizing; D000939:Epitopes; D015699:HIV Envelope Protein gp120; D050505:Mutant Proteins